PFE vs JNJ
Pfizer Inc. vs Johnson & Johnson · Updated Jun 26, 2026
PFE — 9 winsJNJ — 14 wins
Price Performance
PFE -0.60%JNJ +67.72%
Performance
| PFE | JNJ | |
|---|---|---|
| 1 Month | -8.51% | +6.57% |
| 3 Months | -13.34% | +2.31% |
| 6 Months | -6.19% | +18.32% |
| YTD | -5.02% | +18.54% |
| 1 Year | -2.71% | +61.19% |
| 3 Year | -43.33% | +40.27% |
| 5 Year | -34.38% | +64.76% |
Yearly Returns
| YTD | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PFE | -4.3% | -6.4% | -10.8% | -43.8% | -9.4% | +60.4% | -0.8% | -9.4% | +19.8% | +9.8% | +1.6% | +3.0% |
| JNJ | +22.9% | +43.7% | -9.6% | -12.0% | +3.0% | +9.3% | +7.8% | +14.2% | -7.3% | +20.6% | +14.7% | -1.7% |
Valuation
| PFE | JNJ | |
|---|---|---|
| P/E Ratio | 18.05 | 28.36 |
| Forward P/E | 9.08 | 11.17 |
| PEG Ratio | -3.95 | 2.75 |
| P/S Ratio | 2.26 | 5.78 |
| P/B Ratio | 1.59 | 6.86 |
| EV/EBITDA | 12.28 | 17.48 |
Financials
| PFE | JNJ | |
|---|---|---|
| EPS (TTM) | $1.31 | $8.65 |
| Gross Margin | +67.26% | +71.49% |
| Operating Margin | +27.90% | +26.58% |
| Net Margin | +18.60% | +21.76% |
| ROE | +8.31% | +25.92% |
| ROA | +3.61% | +10.47% |
| Debt/Equity | 0.72 | 0.22 |
Growth
| PFE | JNJ | |
|---|---|---|
| Revenue Growth YoY | +5.37% | +9.91% |
| Revenue Growth QoQ | -17.69% | -2.04% |
| EPS Growth YoY | -9.55% | -52.86% |
| EPS Growth QoQ | +262.07% | +1.90% |
Technical
| PFE | JNJ | |
|---|---|---|
| RSI (14) | 24.97 | 64.19 |
| % From 20-Day SMA | -7.35% | +5.21% |
| % From 50-Day SMA | -9.12% | +6.50% |
| % From 200-Day SMA | -8.58% | +13.07% |
| % From 52-Week High | -17.72% | -2.54% |
| % From 52-Week Low | +2.34% | +62.75% |
Analyst Ratings
PFE
Hold(12 analysts)
Strong SellHoldStrong Buy
Price Target
$26.75
+6.09% upside
JNJ
Buy(24 analysts)
Strong SellHoldStrong Buy
Price Target
$251.55
+9.46% upside
Overview
| PFE | JNJ | |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - General | Drug Manufacturers - General |
| Exchange | NYSE | NYSE |
| Market Cap | $142.94B | $556.76B |
| Shares Outstanding | 5.70B | 2.41B |
| Avg Volume (10D) | 55.91M | 9.55M |
| Dividend Yield | 6.86% | 2.27% |
Frequently Asked Questions
Is PFE or JNJ a better buy right now?
Based on 23 comparable metrics, JNJ leads in 14 categories while PFE leads in 9. JNJ has a consensus analyst rating with 24 analysts covering the stock. Neither stock should be purchased based on a single comparison — consider your investment goals and risk tolerance.
Which stock has better performance, PFE or JNJ?
Over the past year, PFE returned -2.71% compared to JNJ's +61.19%. In the short term (1 month), PFE returned -8.51% vs JNJ's +6.57%.
Is PFE or JNJ more expensive?
PFE trades at a P/E of 18.05 compared to JNJ's 28.36. On a price-to-sales basis, PFE trades at 2.26x vs JNJ's 5.78x. Forward P/E: PFE at 9.08 vs JNJ at 11.17.
Which stock has higher growth, PFE or JNJ?
PFE's revenue grew +5.37% year-over-year compared to JNJ's +9.91%. EPS growth: PFE at -9.55% vs JNJ at -52.86%.
Do PFE and JNJ pay dividends?
PFE pays a dividend with a yield of 6.86%. JNJ pays a dividend with a yield of 2.27%.
Which stock do analysts prefer, PFE or JNJ?
PFE has 12 analysts with a target price of $26.75 (+6.09% upside). JNJ has 24 analysts with a target of $251.55 (+9.46% upside).
Data updated daily. All comparisons based on latest available market data. Not investment advice.